Funding sources of therapeutic, vaccine clinical trials for Covid

JAMA Network

About The Study: This analysis of 1,977 clinical trials investigating therapeutics and vaccines for COVID-19 found that most were funded by public sources (58%), followed by industry (27%) and public-private partnerships (15%). Most of these clinical trials focused on COVID-19 therapeutics (85%) as opposed to vaccines (15%).

Authors: Elias Mossialos, Ph.D., of the London School of Economics and Political Science, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.26892)

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.